Literature DB >> 1799186

Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis.

A Yoshida1, K Morozumi, T Suganuma, K Sugito, M Ikeda, T Oikawa, T Fujinami, A Takeda, K Koyama.   

Abstract

This paper describes pathological and clinical investigations of glomerular lesions in bucillamine-induced nephropathy by analyzing biopsy materials from 9 patients with rheumatoid arthritis (RA). There was no specific predisposition for nephrotic syndrome induced by bucillamine in clinical profiles related to age, onset, duration of disease, sex, activity and dose of bucillamine. In light-microscopic, electron-microscopic and immunofluorescent findings, the characteristic changes were similar to those of idiopathic membranous glomerulonephritis (MGN). After discontinuance of bucillamine, the nephrotic syndrome improved slowly with or without corticosteroid therapy. Results confirmed that the most common lesion of nephrotic syndrome associated with bucillamine therapy in RA is MGN. We recommend that corticosteroid therapy should be restricted to cases with severe proteinuria.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1799186     DOI: 10.1159/000168323

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  3 in total

1.  A prospective study of renal disease in patients with early rheumatoid arthritis.

Authors:  Y Koseki; C Terai; M Moriguchi; M Uesato; N Kamatani
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

2.  Bucillamine-induced membranous nephropathy with crescent formation in a patient with rheumatoid arthritis: case report and literature review.

Authors:  Shun Manabe; Mayuko Banno; Marie Nakano; Teruhiro Fujii; Michio Fujiwara; Yasuhiko Kita; Kosaku Nitta; Michiyasu Hatano
Journal:  Case Rep Nephrol Dial       Date:  2014-10-29

3.  Drug-induced kidney disease: a study of the Japan Renal Biopsy Registry from 2007 to 2015.

Authors:  Hitoshi Yokoyama; Ichie Narita; Hitoshi Sugiyama; Michio Nagata; Hiroshi Sato; Yoshihiko Ueda; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2015-11-21       Impact factor: 2.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.